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Cord blood adipokines, neonatal
anthropometrics and postnatal growth in
offspring of Hispanic and Native American
women with diabetes mellitus
April M. Teague1,3, David A. Fields1,3, Christopher E. Aston1, Kevin R. Short1,3, Timothy J. Lyons2,4
and Steven D. Chernausek1,3*
Abstract
Background: Offspring of women with diabetes mellitus (DM) during pregnancy have a risk of developing
metabolic disease in adulthood greater than that conferred by genetics alone. The mechanisms responsible are
unknown, but likely involve fetal exposure to the in utero milieu, including glucose and circulating adipokines. The
purpose of this study was to assess the impact of maternal DM on fetal adipokines and anthropometry in infants of
Hispanic and Native American women.
Methods: We conducted a prospective study of offspring of mothers with normoglycemia (Con-O; n = 79) or type
2 or gestational DM (DM-O; n = 45) pregnancies. Infant anthropometrics were measured at birth and 1-month of
age. Cord leptin, high-molecular-weight adiponectin (HMWA), pigment epithelium-derived factor (PEDF) and
C-peptide were measured by ELISA. Differences between groups were assessed using the Generalized Linear
Model framework. Correlations were calculated as standardized regression coefficients and adjusted for significant
covariates.
Results: DM-O were heavier at birth than Con-O (3.7 ± 0.6 vs. 3.4 ± 0.4 kg, p = 0.024), but sum of skinfolds (SSF)
were not different. At 1-month, there was no difference in weight, SSF or % body fat or postnatal growth between
groups. Leptin was higher in DM-O (20.1 ± 14.9 vs. 9.5 ± 9.9 ng/ml in Con-O, p < 0.0001). Leptin was positively
associated with birth weight (p = 0.0007) and SSF (p = 0.002) in Con-O and with maternal hemoglobin A1c in both
groups (Con-O, p = 0.023; DM-O, p = 0.006). PEDF was positively associated with birth weight in all infants (p = 0.004).
Leptin was positively associated with PEDF in both groups, with a stronger correlation in DM-O (p = 0.009). At 1-month,
HMWA was positively associated with body weight (p = 0.004), SSF (p = 0.025) and % body fat (p = 0.004) across the
cohort.
Conclusions: Maternal DM results in fetal hyperleptinemia independent of adiposity. HMWA appears to influence
postnatal growth. Thus, in utero exposure to DM imparts hormonal differences on infants even without aberrant
growth.
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Background
Children born to mothers with diabetes mellitus
(DM) are at increased risk for development of type 2
diabetes mellitus (T2DM) and other metabolic abnor-
malities later in life. The mechanisms of transmission
to offspring are not yet understood and go beyond
straightforward Mendelian inheritance of susceptibility
genes. Several lines of evidence implicate the in utero
environment as an important factor. First, the risk as-
sociated with maternal DM is greater than that of pa-
ternal DM. Second, fetal exposure to the maternal
diabetic milieu confers additional risk, independent of
other factors. Dabelea and colleagues reported that
offspring conceived after their mother’s DM diagnosis
are nearly four times more likely to develop T2DM
than their siblings born before their mother devel-
oped diabetes, supporting a key role for the fetal en-
vironment [1].
The in utero transmission of risk for diabetes from a
mother to her offspring, whether genetic or environmen-
tal, potentially involves modulation of circulating cyto-
kines that influence appetite regulation, insulin action,
or other metabolic functions. We selected leptin and
high-molecular-weight adiponectin (HMWA) for evalu-
ation because both are produced by adipose tissue and
have been shown in studies of adults or experimental
animals to be associated with insulin resistance, adipos-
ity, fat metabolism, and inflammation.
Pigment epithelial-derived factor (PEDF) is a serpin-
like protein lacking inhibitory function that was selected
for study because expression is known to be influenced
by diabetes and obesity [2, 3], circulating levels are re-
lated to vascular complications of diabetes and insulin
sensitivity [4–6], and it is produced by adipose tissue,
liver, and placenta [7–9]. One prior report found PEDF
expression decreased in placentae from stillborn [10]
and a pilot study noted increased cord blood levels in
pre-eclampsia [11].
We investigated the impact of maternal DM on the
concentrations of these adipokines in fetal circulation
(the in utero milieu) and anthropometric measures at
birth and at 1-month of age in offspring of Hispanic and
Native American women, a population at intrinsically in-
creased risk for the development of T2DM [12].
Methods
Participants were recruited from the University of
Oklahoma Medical Center (Oklahoma City, OK), the
Chickasaw Nation Medical Center (Ada, OK) and the
Choctaw Nation Health Care Center (Talihina, OK) be-
tween April 2010 and October 2013. Signed informed
consent was obtained from a parent of each infant in
accordance with the University of Oklahoma Health
Sciences Center, Chickasaw Nation and/or Choctaw
Nation of Oklahoma Institutional Review Boards, each
of which approved the study.
Offspring of self-identified Native American and His-
panic women with diagnosed gestational or pre-existing
type 2 diabetes mellitus (DM-O group) or confirmed
normoglycemic pregnancies (Con-O group) were en-
rolled at birth into a prospective, longitudinal study of
the impact of in utero exposure to DM on postnatal
growth. Maternal gestational and type 2 diabetes were
diagnosed according to ADA guidelines [13]. Infants
with major malformations, CNS deficit, congenital infec-
tions, severe birth asphyxia (5-min Apgar score <6 or
cord blood pH < 7), congenital metabolic or endocrine
disease or disorders known to affect growth were ex-
cluded from the study. Umbilical cord blood was col-
lected at delivery and cord serum and plasma were
separated by centrifugation and stored at −80 °C until
analysis. Birth weight and length, gestational age, mode
of delivery, five-minute Apgar score and sex were ob-
tained from the hospital birth record. Within 48 h of de-
livery, research staff measured head and abdominal
circumferences and skinfold thickness (subscapular,
abdominal, tricep and thigh) of the neonate. Skinfold
thickness was measured using a Harpenden Skinfold
Caliper (Baty International, West Sussex, UK) by the
study coordinator at each site, each of whom was trained
by an investigator with extensive experience (DAF).
Maternal age at delivery, gestational weight gain,
hemoglobin A1c (if available), results of glucose toler-
ance screenings, pregnancy history, smoking status and
any medications taken during pregnancy were extracted
from medical records. Maternal height and pre-pregnancy
weight were obtained from medical records if recorded, or
by self-report if not, and used to calculate pre-pregnancy
body mass index (BMI).
At 1-month of age, infants visited the CMRI Metabolic
Research Program facilities at the University of Oklahoma
Health Sciences Center for follow-up measurements.
Length, weight, head and abdominal circumferences and
skinfold thickness were measured and body composition
was assessed by dual energy x-ray absorptiometry (DXA;
Lunar iDXA, GE-Healthcare, Fairfield, CT). All DXA
scans were performed and analyzed by the same person
(DAF); suitable scans were obtained in 98.4 % of the
infants.
Leptin, high-molecular-weight adiponectin (HMWA),
pigment epithelium-derived factor (PEDF) and C-peptide
concentrations were measured by ELISA (leptin and
HMWA: R&D Systems, Minneapolis, MN; PEDF and C-
peptide: EMD Millipore, Billerica, MA) according to the
manufacturer’s protocol. All samples were assayed in a
single run. Intra-assay variability for leptin, HMWA,
PEDF and C-peptide were 2.1 %, 3.2 %, 6.9 %, and 5.8 %,
respectively.
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Birth analyses include all mother-infant pairs for
whom umbilical cord blood, anthropometric measures
and maternal records (i.e., the “birth visit”) were avail-
able. Thus, data for 79 out of 94 controls and 45 out of
65 DMs were included. Subjects who had cord blood
samples available were not different from those who did
not in terms of birth anthropometrics or maternal char-
acteristics, except that gestational age was slightly less in
those without cord blood samples in the Con-O group
(39.0 vs 39.6 weeks, p = 0.010; no difference in the DM-
O group). Analyses at 1-month include data on all
infants for whom both the birth and 1-month visits were
completed (53 of 79 Con-O, 36 of 45 DM-O). Partici-
pants who completed only the birth visit were not differ-
ent from those who completed both visits in terms of
gestational age, birth anthropometrics or maternal charac-
teristics. The proportions of infants fed formula and/or
breastmilk were similar between the groups (% breast-
milk/formula/mixed were 24.4/55.6/20.0 in Controls and
20.6/52.9/26.5 in DM). Primary outcomes were infant
weight and length; skinfold thickness; percent body fat;
fat, lean and fat-free mass; cord serum leptin, HMWA,
PEDF and C-peptide.
Group descriptive statistics were expressed as mean ±
standard deviation and grouped frequencies. Differ-
ences between groups were assessed using the General-
ized Linear Model framework. Covariates considered
depended on the outcome variable being analyzed and
included gestational and maternal age, mode of birth
(vaginal or Cesarean), and maternal pre-pregnancy BMI.
The covariates included in the model in each case were
selected using stepwise methods. While cord blood
HMWA and C-peptide values were normally distrib-
uted, leptin and PEDF had skewed sampling distribu-
tions and were logarithmically transformed to meet the
assumptions for linear regression analysis. Correlations
were calculated as standardized regression coefficients
and adjusted for significant covariates. Data analyses
used IBM SPSS Statistics (IBM Corp. Released 2011.
IBM SPSS Statistics for Windows, Version 20.0. Armonk,
NY: IBM Corp). P-values <0.05 were treated as significant
for the purposes of discussion.
Results
Characteristics of mothers
Mothers with DM were 6.4 years older on average and
reported increased parity, pre-pregnancy weight and
BMI compared to control mothers (Table 1). Fifty-seven
percent of control mothers were either overweight (BMI
25.0–29.9 kg/m2) or obese (BMI ≥ 30.0 kg/m2) by Cen-
ters for Disease Control criteria (median BMI = 27.6)
whereas 90 % of DM mothers were overweight or obese
(median BMI = 32.1). Maternal weight gain during preg-
nancy for the DM group was about 3 kg less than that of
control mothers, but not significant. Parity was higher
for DM mothers than for control mothers, possibly
reflecting their older average age.
Women with gestational diabetes comprised the ma-
jority of the DM group (32 GDM vs. 13 T2DM). There
was no difference in cord blood adipokines in offspring
of women with T2DM versus GDM so we combined
them for subsequent analyses. Dysglycemia generally
was well controlled (Table 1), as shown by an average
hemoglobin A1c (HbA1c) (available on 40 of the 45 DM
mothers) of 5.7 ± 0.7 % (range 4.1–8.1 %). Treatments
were as follows: glyburide, 14 mothers; insulin, 18
mothers; metformin, 3 mothers; diet/lifestyle, 7 mothers;
not reported, 3 mothers. Additionally, HbA1c values
were available for 46 of 79 control mothers, all of whom
had normal glucose challenge values, with an average of
5.1 ± 0.3 % (range 4.7–5.9 %; p < 0.0001 versus DM).
Impact of maternal DM on infant body composition and
growth
All infants were born at term (37–42 weeks gestation;
Table 2) according to the WHO standard [14]. DM-O
were delivered slightly earlier (5 days on average; p <
0.0001) than Con-O, but there was no proportional differ-
ence in mode of delivery (vaginal vs. C-section) between
groups. On average, DM-O weighed 0.23 kg more than
Con-O (3.67 ± 0.59 kg vs. 3.44 ± 0.40, p = 0.024), though
length and SSF were equivalent between the groups.
At 1-month of age (Table 2), DM-O continued to be
about 0.2 kg heavier than Con-O (4.7 ± 0.7 kg vs. 4.5 ±
0.5 kg, p = 0.14), but this was no longer a statistically
Table 1 Maternal characteristics
Control DM p-value
N 79 45 –
Age (yr) 24.6 ± 4.4 31.0 ± 6.1 <0.0001
Pre-pregnancy wt (kg) 75.6 ± 18.1 87.4 ± 18.8 0.002
Pre-pregnancy BMI 28.2 ± 6.9 32.7 ± 6.2 0.001
Pregnancy wt gain (kg) 12.6 ± 7.9 9.9 ± 8.3 0.098
Parity 2.2 ± 1.9 3.1 ± 1.8 0.012
HbA1c (%) 5.1 ± 0.3 (n = 46) 5.7 ± 0.7 (n = 40) <0.0001
(mean ± SD; unadjusted)
Teague et al. Reproductive Biology and Endocrinology  (2015) 13:68 Page 3 of 9
significant difference. There also were no between-group
differences in length or SSF and no differences in % fat
in the whole body, trunk or limbs as measured by DXA.
Furthermore, the change in weight, length and SSF from
birth to 1-month did not differ between DM-O and
Con-O (Table 2).
Influence of maternal DM on cord blood adipokine
concentrations
Cord blood leptin concentration was increased 2-fold in
DM-O compared to Con-O (p <0.0001, Table 2) and un-
affected by sex of the infant, mode of delivery, maternal
age, pregnancy weight gain or pre-pregnancy BMI. In
multivariate analyses accounting for gestational age, SSF,
and birth weight (either individually or pairwise), group
designation continued to exert an independent effect on
cord leptin concentration.
Only seven of the 40 mothers for whom data were
available had an HbA1c greater than 6 %. Significant
correlations involving HbA1c remained significant with
and without those seven subjects; therefore we chose to
include them in the analyses. Maternal HbA1c corre-
lated positively with cord leptin level in the entire cohort
(Table 3) and within the separate groups (Fig. 1, Panels a
& b). While both groups showed significant positive cor-
relations, there was a significant difference between the
groups (p = 0.029) with DM-O showing a stronger cor-
relation. Cord PEDF also correlated significantly with
maternal HbA1c when the groups were combined (p =
0.047).
In contrast with leptin, there was no effect of DM sta-
tus on cord blood concentrations of HMWA or C-
peptide.
Cord blood adipokine measures and infant body
composition and growth
Examination of the relationship between leptin and birth
anthropometrics (Table 3) revealed striking group differ-
ences. Birth weight and birth SSF were both highly posi-
tively correlated with cord leptin in the Con-O group
only (Table 3; Fig. 1, Panels c and d). By 1-month of age
(Table 4), the relationships between leptin and body size
and adiposity were no longer apparent; however, change
in weight and SSF from birth to one month was signifi-
cantly negatively correlated with cord leptin in the entire
cohort with no differences in correlation between the
groups.
For PEDF, birth weight was positively correlated (p =
0.0042) with cord concentration (Table 3) and although
the effect was only observed in Con-O, no group differ-
ence was evident. At 1-month (Table 4), neither body
weight nor adiposity (SSF or whole body % fat by DXA)
correlated with cord PEDF concentration. Similarly to
cord leptin, change in weight and SSF from birth to 1-
month was negatively correlated with cord PEDF albeit
only significantly in the entire cohort and the DM-O
group. There was no significant difference in correlation
between the groups.
The relationships between cord HMWA levels and an-
thropometrics differed from that of leptin and PEDF.
Cord HMWA concentration was unrelated to all mea-
sures of adiposity and body size at birth, except for a
positive correlation with maternal pregnancy weight gain
(Table 3). However, at 1-month HMWA was positively
correlated with body weight, SSF and whole body % fat
in all infants, although these reached significance only in
the Con-O group. Furthermore, cord HMWA was posi-
tively associated with the change in weight and SSF from
birth to 1-month in the Con-O group but not in the
DM-O group although the between-group difference
was not significant (Table 4).
Cord blood adipokine interrelationships
Significant correlations were evident among the various
measures (Table 5). HMWA correlated negatively with
Table 2 Infant characteristics
Control-O DM-O p-value
Birth
N 79 45 –
Female/Male 43/36 22/23 0.55
Gestational age (wks) 39.6 ± 0.9 38.9 ± 0.6 <0.0001
Vaginal/C-section Delivery 55/24 31/14 0.93
Weight (kg) 3.4 ± 0.4 3.7 ± 0.6 0.024
Length (cm) 50.1 ± 2.0 49.9 ± 3.0 0.66
Sum of skinfolds (mm) 20.5 ± 4.6 21.6 ± 5.5 0.27
Cord leptin (ng/ml) 9.5 ± 9.9 20.1 ± 14.9 <0.0001
Cord HMWA (ug/ml) 18.2 ± 7.9 16.0 ± 10.4 0.24
Cord PEDF (ug/ml) 3.8 ± 1.4 3.9 ± 1.6 0.78
Cord C-peptide (ng/ml) 0.8 ± 0.5 0.8 ± 0.6 0.91
1-month
N 53 36
Female/Male 29/24 18/18 0.66
Age at testing (d) 35 ± 5 34 ± 5 0.27
Weight (kg) 4.5 ± 0.5 4.7 ± 0.7 0.14
Length (cm) 53.9 ± 2.4 54.1 ± 2.3 0.73
Sum of skinfolds (mm) 37.4 ± 5.8 38.4 ± 8.2 0.54
Total fat by DXA (%) 24.1 ± 3.1 25.1 ± 2.7 0.12
Trunk fat by DXA (%) 17.0 ± 3.5 17.7 ± 3.1 0.34
Limb fat by DXA (%) 38.1 ± 4.9 39.6 ± 4.0 0.13
Change from birth to 1-month
delta Weight (kg) 1.0 ± 0.4 1.0 ± 0.5 0.75
delta Sum of skinfolds (mm) 16.2 ± 6.1 16.6 ± 6.9 0.79
(mean ± SD)
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leptin and PEDF in the group as a whole (Fig. 2, Panels
a and b). Circulating concentrations of leptin and PEDF
were positively correlated (Fig. 2, Panels c and d), with a
stronger correlation observed in the DM-O.
Discussion
We found that maternal DM is associated with fetal
hyperleptinemia and disrupts the normal relationship
between cord blood leptin and infant body composition.
Adiposity at birth (assessed as the sum of skinfold thick-
ness) was unrelated to the concentration of cord leptin
in infants of DM mothers, an effect that was independ-
ent of birth weight and gestational age. Several previous
publications describe increased cord blood leptin levels
in offspring of women with T2DM, T1DM, or GDM.
While there is general agreement that maternal DM
raises cord blood leptin level (save Pirc et al [15] and
Lea et al [16], who report no such effect), there is con-
troversy about underlying mechanisms. Indeed, Okereke
et al [17] found that, while cord leptin levels were
higher in infants of gestational DM than non-diabetic
mothers, adjustment for infant fat mass abrogated the
relationship, leading to the conclusion that the effect of
maternal DM is due to increased fetal adiposity. This
contrasts with our findings, in which birth adiposity is
unrelated to cord leptin in infants of DM mothers. The
reason for this discrepancy is not entirely clear but may
relate to differing methods for determining fat mass
and/or different study populations. In a study of mostly
T1DM women, Persson et al [18] reported increased
cord leptin in DM offspring with no correlation with
birth weight in the infants of mothers with DM.
Similarly, Gross and colleagues [19] found that the pres-
ence of maternal DM correlated with cord blood leptin,
independent of birth weight. The latter two studies,
although lacking measures of adiposity, support our
conclusion that an increase in fetal fat mass does not
explain the effect of maternal DM on cord leptin
concentration.
Our data suggest that maternal glycemia is a dominant
determinant of fetal leptin concentration. We found a
positive relationship between cord leptin and maternal
HbA1c in offspring of diabetic mothers, in agreement with
two prior studies [20, 21]. Additionally, we observed a
Table 3 Correlationsa of cord blood measures with birth, pregnancy and pre-pregnancy measures
All p-value Number Control-O p-value Number DM-O p-value Number Between-group p-value
Leptinb DM Gage, parity –
Birth weight 0.23 0.009 121 0.38 0.0007 79 0.15 0.34 42 0.025
Birth SSF 0.22 0.010 110 0.36 0.002 74 0.10 0.64 36 0.025
Maternal Age 0.00 0.99 120 0.01 0.97 78 0.03 0.86 42 0.79
Maternal Pre-pregnancy BMI 0.19 0.047 101 0.24 0.06 64 0.05 0.78 37 0.29
Pregnancy weight gain 0.10 0.28 101 0.05 0.70 64 0.12 0.46 37 0.98
Maternal HbA1c 0.38 0.0003 80 0.32 0.023 43 0.44 0.006 37 0.029
HMWA DM – –
Birth weight 0.07 0.47 124 0.00 0.99 79 0.18 0.23 45 0.35
Birth SSF 0.10 0.29 113 −0.02 0.86 74 0.28 0.09 39 0.10
Maternal Age −0.06 0.50 123 0.00 0.99 78 0.01 0.96 45 0.98
Maternal Pre-pregnancy BMI −0.16 0.12 104 −0.16 0.20 64 −0.11 0.52 40 0.99
Pregnancy weight gain 0.30 0.002 104 0.13 0.29 64 0.47 0.002 40 0.027
Maternal HbA1c −0.08 0.48 86 0.12 0.42 46 −0.05 0.78 40 0.44
PEDFb DM – gender
Birth weight 0.26 0.004 124 0.28 0.014 79 0.17 0.24 45 0.56
Birth SSF 0.13 0.19 118 0.21 0.07 79 0.17 0.31 39 0.30
Maternal Age 0.20 0.07 123 0.10 0.39 78 0.26 0.07 45 0.54
Maternal Pre-pregnancy BMI 0.16 0.14 104 0.20 0.11 64 −0.02 0.91 40 0.59
Pregnancy weight gain −0.02 0.82 104 −0.10 0.42 64 0.10 0.54 40 0.36
Maternal HbA1c 0.24 0.047 86 0.18 0.22 46 0.19 0.21 40 0.64
aCorrelations shown are standardized correlation coefficients from the regression of cord blood measures on the birth, pregnancy or pre-pregnancy measure with
adjustment for significant covariates. Covariates considered were diabetic status (DM), gender, gestational age at birth (Gage), mode of delivery (mode), maternal
age and parity. Significant covariates are indicated in italic font
bLeptin and PEDF were log transformed for analysis. (p ≤ 0.05 in bold)
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correlation between cord leptin and maternal HbA1c
in the controls. Neither cited study examined the rela-
tionship with fetal leptin and maternal glycemia in un-
complicated pregnancies. In fact, the results of our
study are consistent with data from the HAPO study of
more than 20,000 non-diabetic pregnancies, which
show that modest increments in maternal glycemia are
associated with increases in birth weight [22]. Thus,
the degree of glucose exposure during normal preg-
nancy plausibly underlies the relationship of adiposity
and leptin.
Another important finding in our study is the rela-
tionship between cord blood adiponectin and adiposity
at 1-month of age. Although the broader significance
of this finding is unclear at this time, adiponectin levels
remain elevated (relative to adult values) for the first
six months of life [23], supporting the notion that the
adipokine is involved in the expansion of fat mass fol-
lowing birth. Several previous studies, like ours, find
no effect of maternal DM on cord blood adiponectin
concentration [24, 25], whereas others report a modest
decrease [26]. Similarly, some, but not all, studies
report positive correlations with birth anthropometrics
[24, 27, 28]. The reasons for these differences are un-
clear, but may reflect differing assay methodologies
and whether total or high molecular weight adiponec-
tin was measured.
The role of PEDF during human development and
childhood is largely unexplored. We found a modest re-
lationship between birth weight and cord blood PEDF
overall with no differences between infants born to
mothers with DM versus controls. However, there were
striking correlations with cord blood levels of both
HMWA (negative) and leptin (positive). The strongest
relationship was between leptin and PEDF in the off-
spring of DM mothers, wherein 38 % of the variation in
leptin concentration was explained by PEDF level.
Although the basis for this relationship is unclear, it could
be reflect the need for the angiogenic properties of leptin
to be balanced by the anti-angiogenic effects of PEDF in
the placenta, a putative source of cord blood leptin and
PEDF [10, 29]. PEDF has been shown to inhibit leptin
induced angiogenesis in vitro [30]. Furthermore, Böhm
et al have found a common genetic variation in the
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Fig. 1 Association of cord blood leptin with maternal hemoglobin A1c. Association of cord blood leptin with maternal hemoglobin A1c (HbA1c)
during pregnancy in Con-O (Panel a) and DM-O (Panel b) and with birth adiposity in Con-O (Panel c) and DM-O (Panel d). Open circles represent
Con-O; closed circles represent DM-O
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PEDF gene among individuals at risk for T2DM that is
associated with increases in circulating concentrations of
both PEDF and leptin [31], providing an additional link
between these cytokines as well a potential explanation
for the relationship.
The strengths of this study are the careful phenotyping
of the infants at birth, the detailed measures of growth
and body composition over the first month of life, and
the new insights concerning potential determinants of
cord leptin, PEDF, and the connection between HMWA
and the acquisition of adipose tissue. The conclusions,
however, are based on correlations and thus cause and
effect relationships remain to be determined. In addition,
we do not know whether the observations concerning
PEDF and leptin reflect changes in expression by pla-
centa or other fetal tissues such as liver or adipose de-
pots. A potential limitation is the attrition between the
birth and 1-month visits (due largely to inability to reach
the mothers by phone, letter or email). However, there
were no obvious distinctions between subjects who com-
pleted only the birth visit and those who completed both
visits, suggesting this had minimal impact on our find-
ings. Treatment modalities varied amongst the DM
mothers, with glyburide and insulin most commonly
prescribed. Though neither birth weight [32] nor neo-
natal adiposity [33] appear to be affected differently by
glyburide versus insulin, we cannot rule out the possibil-
ity that other outcomes may be impacted by treatment.
Table 4 Correlationsa of measures at 1 month with cord blood measures
All p-value Number Control-O p-value Number DM-O p-value Number Between-group p-value
Leptin
1-month weight 0.04 0.69 86 0.04 0.77 53 −0.11 0.55 33 0.46
1-month SSF −0.06 0.61 84 0.01 0.95 51 −0.22 0.22 33 0.22
1-month % Total Fat 0.20 0.06 85 0.19 0.19 52 0.07 0.72 33 0.61
Δ Weight (birth to 1-month) −0.37 0.0005 86 −0.35 0.009 53 −0.49 0.004 33 0.21
Δ SSF (birth to 1-month) −0.29 0.010 77 −0.27 0.07 48 −0.45 0.015 29 0.25
HMWA
1-month weight 0.26 0.004 89 0.29 0.038 53 0.18 0.30 36 0.65
1-month SSF 0.24 0.025 87 0.21 0.15 51 0.27 0.11 36 0.69
% Total fat at 1-month 0.30 0.004 88 0.32 0.022 52 0.30 0.07 36 0.49
Δ Weight (birth to 1-month) 0.22 0.044 89 0.40 0.003 53 0.06 0.77 36 0.10
Δ SSF (birth to 1-month) 0.21 0.07 80 0.30 0.041 48 0.11 0.54 32 0.35
PEDF
1-month weight 0.03 0.81 89 0.11 0.49 53 −0.09 0.65 36 0.73
1-month SSF 0.01 0.91 87 0.14 0.32 51 −0.16 0.42 36 0.16
% Total fat at 1-month 0.12 0.23 88 0.07 0.59 52 0.10 0.59 36 0.58
Δ Weight (birth to 1-month) −0.31 0.003 89 −0.16 0.26 53 −0.52 0.005 36 0.15
Δ SSF (birth to 1-month) −0.19 0.11 80 −0.04 0.78 48 −0.46 0.019 32 0.20
aCorrelations shown are standardized correlation coefficients from the regression of the 1-month measures on the cord blood measure with adjustment for
significant covariates. Covariates considered were diabetic status (DM), gender, age in days
bLeptin and PEDF were log transformed for analysis. (p ≤ 0.05 in bold)
Table 5 Correlations among cord blood hormones
All p-value Number Control-O p-value Number DM-O p-value Number Between-group p-value
Leptin
HMWA −0.34 0.0002 121 −0.35 0.0017 79 −0.29 0.06 42 0.94
PEDF 0.45 <0.0001 121 0.43 <0.0001 79 0.62 <0.0001 42 0.009
C-peptide −0.01 0.91 121 −0.18 0.11 79 0.18 0.26 42 0.052
HMWA
PEDF −0.30 0.0009 124 −0.27 0.014 79 −0.32 0.031 45 0.58
C-peptide 0.07 0.46 124 0.06 0.62 79 0.08 0.61 45 0.86
(p ≤ 0.05 in bold)
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Finally, other metabolic changes that are coincident with
maternal DM (e.g. hyperlipidemia) were not assessed.
Future studies will be required to dissect out which of
the effects reflect changes induced by maternal meta-
bolic aberration and which may be due to specific gen-
etic variations passed on to offspring and to what extent
they relate to long term health of the offspring.
Conclusions
Cord blood leptin at term is increased by maternal dia-
betes independently of neonatal adiposity and is directly
related to maternal hemoglobin A1c percent in offspring
of diabetic and non-diabetic women. These data provide
further evidence that infants born to mothers with near-
optimal management of diabetes still show the effects of
the condition and that the level of maternal glycemia
has a major influence on leptin secretion. In contrast,
PEDF concentration is unaffected by dysglycemia, but
correlates with birth weight and leptin, suggesting a
novel role(s) for this understudied cytokine in fetal
growth control and placental function. Lastly, higher
levels of cord blood HMWA were associated with
increased infant growth and adiposity at 1 month, sup-
porting a role for HMWA in the acquisition of fat mass
during infancy.
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